International Society of Blood Transfusion

GT Biopharma Presents TriKE® Nanobody Pipeline (GTB-5550) Preclinical Multiple Myeloma Proof-of-Concept Data at 2022 EBMT Annual Meeting

Retrieved on: 
Monday, March 21, 2022
Company, International Society of Blood Transfusion, Compugen (Israeli company), University, Cytotoxicity, EBMT, NASDAQ, Therapy, Bortezomib, CD16, FV, The Company, Survival, Division, Doctor of Philosophy, Multiple myeloma, CD276, Trike, Assistant, MD, Transplant, Lenalidomide, MDSC, Blood, ANOVA, Vaccine, NK, Hematology

BRISBANE, Calif., March 21, 2022 /PRNewswire/ -- GT Biopharma, Inc. ("the Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary tri-specific natural killer (NK) cell engager, TriKE® protein biologic technology platform, announced today, preclinical data to be presented at the hybrid 48th European Society for Blood and Marrow Transplantation Annual Meeting (EBMT). The poster presentation titled, "Tri-specific Killer Engager (TriKE®) against B7-H3 enhances NK cell mediated killing of multiple myeloma," is presented by Aimee Merino, MD, PhD, Assistant Professor of Medicine, Division of Hematology, Oncology and Transplantation at the University of Minnesota. GTB-5550 (B7-H3 TriKE) is the Company's tri-specific killer engager (TriKE) with camelid single-chain Fv fragments against B7-H3 (CD276) and CD16 linked by IL-15 to enhance NK cell killing of myeloma. GTB-5550 is part of GT Biopharma's portfolio of lead TriKE product candidates being investigated as a mono- and combination therapy against multiple myeloma.

Key Points: 
  • GTB-5550 is part of GT Biopharma's portfolio of lead TriKE product candidates being investigated as a mono- and combination therapy against multiple myeloma.
  • Dr. Gregory Berk, President of R&D and Chief Medical Officer noted, "Testing GTB-5550 across several multiple myeloma cell-lines has yielded preclinical evidence suggesting further investigation of this TriKE in the clinic.
  • Background -Natural Killer (NK) cell-based therapies hold great promise in treating multiple myeloma.
  • One method to enhance NK cell specificity against myeloma is antibody dependent cellular cytotoxicity through a CD16 receptor.

Kuwait Central Blood Bank Chooses Biolog Transfusion Solution to Upgrade Blood Components’ Management

Retrieved on: 
Tuesday, August 31, 2021
Technology, Medical Devices, Professional Services, Software, Other Health, Biotechnology, General Health, Health, Data Management, Other Professional Services, Company, Synthase, AABB, Health care, Health professional, Kuwait Central Blood Bank, Therapy, Software, RFID, Efficiency, Red blood cell, Government, Accreditation, American Association, Ministry of Health (Saudi Arabia), Asia, Awareness, Achievement, List of life sciences, Ministry, International Society, Safety, Patient, KCBB, ATC, International Society of Blood Transfusion, COVID-19, Platelet, Technology, Pharmaceutical industry, Medical device, Medical imaging

After a public consultation, biolog-id, a global service provider of connected healthcare solutions, through its local partner ATC, has been awarded by the Ministry of Health to deploy Biolog Transfusion Solution in Kuwait Central Blood Bank (KCBB), the national blood bank operator.

Key Points: 
  • After a public consultation, biolog-id, a global service provider of connected healthcare solutions, through its local partner ATC, has been awarded by the Ministry of Health to deploy Biolog Transfusion Solution in Kuwait Central Blood Bank (KCBB), the national blood bank operator.
  • While the COVID-19 pandemic has challenged the transfusion supply chain, KCBB has chosen to adopt the cutting-edge technology Biolog Transfusion Solution to better drive its operations.
  • Biolog Transfusion Solution will be deployed in the Kuwait Central Blood Bank as well as three distant Blood Banks.
  • About Kuwait Central Blood Bank:
    The Kuwait Central Blood Banks (KCBB) mission is meeting the countrys needs of the patients for safe, high quality and provision of all transfusion services under the supervision of the government.

Cerus Corporation Announces the Inclusion of Pathogen Reduction Technology in the ISBT Working Party Recommendations for the Preparation of COVID-19 Convalescent Plasma

Retrieved on: 
Thursday, April 2, 2020
Medical Supplies, Health, Medical devices, Infectious diseases, Practice Management, Cardiology, Biotechnology, Transfusion medicine, Medical specialties, Medicine, Branches of biology, International Society of Blood Transfusion, Blood transfusion, Influenza A virus subtype H1N1, Influenza

Cerus Corporation (Nasdaq: CERS) announced today that the International Society of Blood Transfusion (ISBT) Working Party on Global Blood Safety issued a new document titled Points to consider in the preparation and transfusion of COVID-19 convalescent plasma.

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) announced today that the International Society of Blood Transfusion (ISBT) Working Party on Global Blood Safety issued a new document titled Points to consider in the preparation and transfusion of COVID-19 convalescent plasma.
  • Convalescent plasma has emerged as a promising potential therapeutic to treat acutely ill COVID-19 patients, said Dr. Laurence Corash, Cerus chief scientific officer.
  • These just issued recommendations by the ISBT Working Party on Global Blood Safety provide a framework for institutions involved in collecting, manufacturing, and transfusing COVID-19 convalescent plasma.
  • Convalescent plasma has been cited as a potential therapy for viral infection dating back to the 1918 Spanish influenza A (H1N1) pandemic.

Cerus Corporation Announces Presentations Highlighting INTERCEPT Blood System at the 29th Regional Congress of the ISBT

Retrieved on: 
Monday, June 24, 2019
Medical Supplies, Health, Medical devices, Hospitals, Clinical trials, Transfusion medicine, Hematology, Body fluids, Anatomy, Medicine, Blood, International Society of Blood Transfusion, Blood transfusion, ISBT, Transfusion

Cerus Corporation (Nasdaq:CERS) announced today that multiple abstracts featuring the INTERCEPT Blood System pathogen reduction technology, including four oral presentations, will be included in the scientific program at the 29th regional congress of International Society of Blood Transfusion (ISBT).

Key Points: 
  • Cerus Corporation (Nasdaq:CERS) announced today that multiple abstracts featuring the INTERCEPT Blood System pathogen reduction technology, including four oral presentations, will be included in the scientific program at the 29th regional congress of International Society of Blood Transfusion (ISBT).
  • The symposium will feature presentations titled Safeguarding the Blood Supply Against (Re)emerging Pathogens and Balancing Blood Safety and Economics.
  • Cerus Corporation is dedicated solely to safeguarding the worlds blood supply and aims to become the preeminent global blood products company.
  • INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

ISBT Satellite Symposium Co-hosted by Ortho Clinical Diagnostics and Quotient Discusses Responding to the Challenges of Resource Constraints in Transfusion Diagnostics

Retrieved on: 
Friday, June 1, 2018
Medicine, Transfusion medicine, Anatomy, Hematology, Health, Medical tests, Ortho Clinical Diagnostics, Ortho, Blood, Blood transfusion, Immunohaematology, International Society of Blood Transfusion

RARITAN, N.J., June 1, 2018 /PRNewswire/ --Ortho Clinical Diagnostics (Ortho), a global leader of in vitro diagnostics, today announced that it will host a satellite symposium, co-sponsored with Quotient Limited (QTNT), titled "Responding to the Challenges of Resource Constraints in Transfusion Diagnostics", during the 35th International Congress of the International Society of Blood Transfusion (ISBT).

Key Points: 
  • RARITAN, N.J., June 1, 2018 /PRNewswire/ --Ortho Clinical Diagnostics (Ortho), a global leader of in vitro diagnostics, today announced that it will host a satellite symposium, co-sponsored with Quotient Limited (QTNT), titled "Responding to the Challenges of Resource Constraints in Transfusion Diagnostics", during the 35th International Congress of the International Society of Blood Transfusion (ISBT).
  • "The speakers at our symposium will identify the critical challenges facing transfusion medicine now and in the future," said Heidi Casaletto, vice president of Transfusion Medicine at Ortho.
  • Ortho will also share the following poster presentations at ISBT:
    Presenters: Tony S. Casina of Ortho Clinical Diagnostics, Raritan and Wim Malomgre of Ortho Clinical Diagnostics, Turnhout, Belgium
    Presenters: Tony S. Casina of Ortho Clinical Diagnostics, Raritan and Wim Malomgre of Ortho Clinical Diagnostics, Turnhout, Belgium
    Additionally, at ISBT, Ortho will feature the award-winning ORTHO VISION platform, which has received a string of accolades for its ability to innovate in transfusion medicine.
  • Ortho Clinical Diagnostics is a global leader of in vitro diagnostics serving the clinical laboratory and immunohematology communities.